Episode 26: Asia’s 2025 Q1 Report: Global Trends in Biopharma Transactions
During the Asia-focused Episode 26 of Biotalk, Geoff Meyerson, CEO of Locust Walk, shares fresh insights from Japan, China, and Korea, […]
Uncategorized
2025
Uncategorized
Biotalk Episode 25: 2025 Q1 Report: Global Trends in Biopharma Transactions
Podcast: Play in new window | Download (Duration: 13:17 — 30.4MB)
Subscribe: Apple Podcasts | Spotify | RSS
During Episode 25 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q1 Report: Global Trends in Biopharma
Insight, Locust Walk Insights, Market Trends, Quarterly Reports
2025 Q1 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q1 Report applies the latest data to analyze the current landscape in life sciences deals.
Insight, Locust Walk Insights, Market Trends, Quarterly Reports
China Supermarket: Is the Value for Money Due to Global Development Expertise or Superior Negotiation?
Locust Walk analyzed the evolving landscape of China’s biotech out-licensing market and its impact on global dealmaking.
News
Sun Pharma to Acquire Checkpoint Therapeutics
LOCUST WALK NEWS Sun Pharma to Acquire Checkpoint Therapeutics Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment
Uncategorized
Biotalk Episode 24: Asia’s 2024 Year-In-Review
Podcast: Play in new window | Download (Duration: 12:29 — 28.6MB)
Subscribe: Apple Podcasts | Spotify | RSS
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, explores the evolving biotech landscapes in Japan and China,
Uncategorized
Biotalk Episode 23: 2024 Year-In-Review Report: Global Trends in Biopharma Transactions
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Year-In-Review Report: Global Trends in Biopharma
Insight, Locust Walk Insights, Market Trends, Quarterly Reports
2024 Year-In-Review Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings.